Chimeric antigen receptor (CAR) T cells provide an effective treatment option for advanced haematological malignancies, but neurological adverse effects of CAR T cell therapies are common. This article reviews current knowledge regarding the mechanisms that contribute to neurological toxicities following CAR T cell therapy and highlights current and emerging management strategies.
- Philipp Karschnia
- Jörg Dietrich